Singapore-founded health technology startup Mesh Bio has announced the regulatory approval of its HealthVector® Diabetes as a Software Medical Device (SaMD) by the Health Sciences Authority (HSA). HealthVector® Diabetes will be involved in an implementation pilot at Singapore General Hospital (SGH), Tan Tock Seng Hospital (TTSH), and selected polyclinics for potential clinical adoption.